Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. (HOOK) has described itself as a clinical-stage biopharmaceutical company developing next generation immunotherapeutics based on a proprietary arenavirus platform. Its news flow has highlighted programs in oncology and serious infectious diseases, including product candidates targeting HPV16-positive cancers, KRAS mutated cancers, and viral infections such as hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
Company press releases provide detailed updates on its collaboration and license agreement with Gilead Sciences, Inc. For example, HOOKIPA has reported on the HB-400 program in clinical development for HBV and the HB-500 program, a next-generation therapeutic vaccine being evaluated as a potential component of a curative regimen for HIV. News items have described clinical milestones such as enrollment completion in a Phase 1b trial of HB-500, including trial design elements and the intended role of HB-500 in a combination strategy for a potential functional cure of HIV.
HOOKIPA’s news coverage has also included significant corporate and strategic developments. In early 2025, the company issued multiple announcements related to a potential all-share combination with Poolbeg Pharma plc and associated U.K. Takeover Code disclosure requirements, followed by a Rule 2.8 statement that it did not intend to make an offer under Rule 2.7 of the Code. Subsequent releases detailed an asset purchase agreement with Gilead for HOOKIPA’s HB-400 program assets and certain HB-500 assets, and explained how this transaction related to the company’s long-term prospects and strategies.
Later announcements document HOOKIPA’s intention to voluntarily delist its common stock from the Nasdaq Capital Market, deregister its common stock under the Securities Exchange Act of 1934, and seek stockholder approval for dissolution and liquidation. Investors using this news page can review the sequence of clinical updates, collaboration news, U.K. takeover-related disclosures, and corporate actions such as the asset sale to Gilead, the special meeting of stockholders, and the steps toward delisting and deregistration. This provides a consolidated view of both scientific progress and material corporate events affecting HOOKIPA and the HOOK symbol.
Summary not available.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announces participation in the SVB Leerink’s CybeRx Series: Vaccine Forum on September 23-24, 2020. A fireside chat featuring CEO Joern Aldag and CMO Igor Matushansky will occur on September 23 at 12:00 PM ET. HOOKIPA focuses on developing immunotherapeutics for infectious diseases and cancers using their proprietary arenavirus platform. Their technologies include non-replicating and replicating platforms, with a Phase 2 trial ongoing for a Cytomegalovirus vaccine. They also collaborate with Gilead Sciences for HIV and Hepatitis B research.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) has announced its participation in several virtual investor conferences in September 2020, featuring key presentations. The conferences include the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, where HOOKIPA will present on September 14 at 10:30 AM ET. Other notable events include the Morgan Stanley Virtual Global Healthcare Conference and the BofA Global Healthcare Conference. The company specializes in immunotherapeutics targeting infectious diseases and cancers, utilizing its proprietary arenavirus platform.
HOOKIPA Pharma reported its Q2 2020 financial results, highlighting a revenue increase to $6.7 million from $4.1 million year-over-year, mainly due to Gilead collaboration reimbursements. The company’s cash position stood at $93.3 million, down from $113.6 million at the end of 2019. R&D expenses decreased to $11.6 million, while G&A expenses rose slightly to $4.3 million. Net loss improved to $7.1 million compared to $12.1 million in Q2 2019. Notably, interim results for the Phase 2 trial of HB-101 showed positive safety and immunogenicity, with ongoing trials for HB-201 and HB-202 progressing well.
HOOKIPA Pharma (NASDAQ: HOOK) announced positive interim results from its Phase 2 clinical trial of the HB-101 CMV vaccine, aimed at kidney transplant patients. The trial, involving 51 CMV-negative individuals, showed that 84% experienced minimal adverse events, indicating good tolerability. Among participants receiving three doses, 100% mounted CMV-neutralizing antibodies. Furthermore, 100% of those receiving three doses exhibited a cellular immune response. The company plans to release preliminary efficacy data by the end of 2020.
HOOKIPA Pharma (NASDAQ: HOOK) announced the resignation of Dr. Sander van Deventer as a Non-Executive Director of its Board, effective immediately. He joined the Board in 2011 but will continue his role in the Scientific Advisory & Review Committee. The Board now consists of 8 members, with Dr. Jan van de Winkel as Chairman. HOOKIPA focuses on developing immunotherapeutics targeting infectious diseases and cancers, utilizing its proprietary arenavirus platform. Key projects include a Phase 2 CMV vaccine and collaborations with Gilead for HIV and Hepatitis B.
HOOKIPA Pharma, a clinical-stage biopharmaceutical company, will present at the Jefferies Virtual Healthcare Conference from June 2-4, 2020. CEO will speak on June 3, 2020, at 8:30 a.m. ET. The presentation will focus on HOOKIPA's innovative immunotherapeutic platform targeting infectious diseases and cancers. Their proprietary technologies, VaxWave and TheraT, aim to enhance immune responses against diseases like CMV and HPV. The company is also collaborating with Gilead Sciences to develop treatments for HIV and hepatitis B.
Summary not available.
Summary not available.